Latest News

Key Insights Using the 2 Stage Free Cash Flow to Equity, Shimano fair value estimate is JP¥32,223 Shimano is estimated...

There wouldn't be many who think Yamaha Motor Co., Ltd.'s ( TSE:7272 ) price-to-sales (or "P/S") ratio of 0.5x is worth...

Key Insights Given the large stake in the stock by institutions, AGC's stock price might be vulnerable to their trading...

There wouldn't be many who think Shiseido Company, Limited's ( TSE:4911 ) price-to-sales (or "P/S") ratio of 1x is...

Somerset Minerals Limited ( ASX:SMM ) insiders who purchased shares in the last 12 months were richly rewarded last...

Key Insights Significant control over Endeavour Group by retail investors implies that the general public has more...

Recent performance and business profile Clal Insurance Enterprises Holdings (TASE:CLIS) has drawn investor attention after recent price moves, with the share closing at ₪210.9 and showing mixed short term returns alongside stronger multi year total returns. The company operates across several areas in Israel, including insurance, pensions, provident funds, finance, and credit insurance. This gives it multiple revenue streams tied to both long term savings and protection products. For readers...

Earlier this week, the U.S. Supreme Court postponed a decision on the legality of tariffs affecting import-heavy retailers, leaving companies like Kohl’s facing ongoing uncertainty around their cost structure and pricing power. This delay keeps tariffs as a live risk factor for Kohl’s, potentially complicating efforts to manage margins at a time when its traditional department-store model is already under pressure. We’ll now look at how this tariff-related legal uncertainty reshapes Kohl’s...

While it’s been a great week for Lotus Resources Limited ( ASX:LOT ) shareholders after stock gained 16%, they should...

As global markets continue to navigate geopolitical tensions and economic shifts, Asian equities have shown resilience, with several indices experiencing notable gains. In this environment, identifying undervalued stocks becomes crucial for investors seeking opportunities amidst fluctuating market conditions.

As 2026 begins, Asian markets are capturing attention with their dynamic movements, particularly as investors navigate the broader global economic landscape. Penny stocks, though often seen as a niche investment area, continue to hold potential for those seeking value and growth in smaller or newer companies. Despite being an older term, penny stocks can still offer significant opportunities when backed by strong financial health; here we explore a few that stand out for their promising...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

JPMorgan’s new coverage of TIC Solutions (TIC), highlighting its technical depth and acquisition integrations, has put the stock in focus as investors weigh cross-selling prospects and planned cost synergies against a recent earnings miss. See our latest analysis for TIC Solutions. The JPMorgan coverage has arrived after a choppy stretch for TIC Solutions, with a 90 day share price return of a 10.2% decline but a year to date share price return of 15.77%. The 1 year total shareholder return...

Rhythm Pharmaceuticals recently reported preliminary unaudited 2025 results showing IMCIVREE net product revenues of about US$57 million in the fourth quarter and US$194 million for the full year, both reflecting solid growth versus earlier periods. An interesting aspect of this update is that roughly two-thirds of IMCIVREE revenue still comes from the U.S., underlining how central that market remains to Rhythm’s commercial story even as global sales expand. We’ll now examine how this...

Recently, Citizens began covering Tri Pointe Homes with a "Market Outperform" rating, coinciding with a fall in average two-year fixed mortgage rates below 4% and management comments about encouraging early demand signs for 2025 despite a weaker backlog. This combination of a new supportive analyst view, easing financing costs for buyers and cautious management optimism has sharpened investor attention on how Tri Pointe might perform if housing demand continues to stabilize. Next, we’ll...

OTC Markets Group recently announced that Granite Real Estate Investment Trust has qualified to trade on the OTCQX Best Market under the symbol “GRTUF,” while also closing a US$6.06 million shelf registration tied to an ESOP-related offering of 100,000 units. This OTCQX listing gives U.S. investors more convenient access to Granite REIT’s disclosures and real-time trading information, potentially broadening its investor base. We’ll now examine how easier U.S. market access through the new...

Altius Minerals recently reported past fourth-quarter 2025 Project Generation activity, including new investments in Centauri Minerals and Perseverance Metals, plus share consideration and a 1.5% net smelter return royalty from vending the Firenze gold project and equity received for the Celts project. An interesting angle is the scale of the exploration pipeline linked to these holdings, with more than 75,000 metres of discovery-focused drilling planned by portfolio and royalty-linked...

QBE Insurance Group (ASX:QBE) is drawing fresh attention after QBE Re launched George Street Re, a casualty sidecar with capital of more than $550 million that adds fully collateralised support to its global casualty reinsurance portfolio. See our latest analysis for QBE Insurance Group. Against this backdrop, QBE Insurance Group’s A$20.10 share price sits after a 4.96% 1 month share price return and a 6.86% 3 month share price decline, while its 5 year total shareholder return of 172.77%...

La-Z-Boy (LZB) has been drawing attention after recent share price moves, with the stock closing at $39.58 and showing mixed returns over the past year, month, and past three months. See our latest analysis for La-Z-Boy. The recent 1-day share price return of 1.44% and 7-day share price return of 6.11% come on top of a 23.19% 90-day share price return. At the same time, the 1-year total shareholder return is 6.79% lower and the 3-year total shareholder return is 58.90% higher. This suggests...

Aquestive Therapeutics recently disclosed that the FDA has identified unspecified deficiencies in the New Drug Application for its orally delivered epinephrine film Anaphylm, pausing labeling discussions and potentially affecting the timing of any approval decision ahead of the scheduled 31 January 2026 PDUFA date. At the same time, the company is pressing ahead with plans to seek approvals for Anaphylm in Canada, Europe, and the UK in 2026, signaling an effort to build a global,...

Apogee Enterprises (APOG) drew fresh attention after disappointing third quarter results, a reduced fiscal 2026 outlook, and the resignation of its Chief Financial Officer coincided with a sharp one day share price drop. See our latest analysis for Apogee Enterprises. The recent selloff came on top of already weak momentum, with a 30 day share price return showing an 11.6% decline and a 1 year total shareholder return showing a 28.7% decline. This suggests sentiment has been fading even...

Singapore Exchange Limited has appointed Ivan Han as Chief Risk Officer, succeeding Agnes Koh, with the transition formally taking effect on April 1, 2026, while Koh moves into a special advisory role later that year. The handover places a long-serving internal risk leader with deep derivatives and clearing experience at the centre of SGX’s risk framework just as regulatory engagement and multi-asset expansion remain central to its business model. We’ll now examine how this Chief Risk...

In recent days, Barclays initiated coverage on RLJ Lodging Trust with a Sell rating, coinciding with a period of increased insider selling activity. This combination of cautious analyst sentiment and insiders reducing exposure may raise fresh questions about how investors perceive RLJ Lodging Trust’s prospects. We’ll now look at how Barclays’ cautious stance and insider selling could shape RLJ Lodging Trust’s broader investment narrative for investors. The end of cancer? These 29 emerging...

If you are wondering whether Sabra Health Care REIT is offering fair value at today's price, you are not alone. This article is built to help you weigh what the current share price might mean for you as an investor. The stock last closed at US$19.28, with returns of 0.7% over the past week, 0.5% over the past month, 0.7% year to date, 24.4% over the past year, 87.0% over three years, and 64.9% over five years. These figures may have caught the eye of investors thinking about growth potential...